1. Introduction {#s0005}
===============

"Survival rates have improved for almost every disease of every organ in the last few decades, with one notable exception: liver disease" \[[@bb0005]\]. This statement by *The Lancet Commission* clearly illustrates the global burden of liver disorders and the need for more effective therapeutic strategies \[[@bb0010]\]. The most frequently occurring liver diseases include hepatitis, liver cancer, alcoholic liver disease, fatty liver disease, and hereditary diseases. In addition to direct harmful effects, these diseases can significantly affect the liver's carbohydrate, fat, and protein metabolism. The increase in lifestyle-related incidence rates and the limited therapeutic efficacy of currently available treatments have resulted in substantial drug development efforts targeting the liver \[[@bb0010]\]. Our ability to treat hepatic diseases by targeting their genetic background is increasingly becoming a clinical reality owing to the development of nucleic acid-based therapeutics. In contrast to small molecule drugs and biologics which target gene products (*i.e.* proteins), nucleic acid therapeutics have the potential to therapeutically regulate essentially any gene of interest at the DNA or RNA level. Their versatility in treating inherited or acquired disorders originating in the liver stems from the ability to induce efficient gene silencing (inhibiting pathological/mutant protein production), gene expression (producing therapeutic proteins) or gene editing (correcting dysfunctional/mutated genes). Several nucleic acid therapeutics have been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) with many more in various stages of clinical evaluation. These therapeutics include antisense oligonucleotides (ASO) \[[@bb0015]\], small interfering RNA (siRNA) \[[@bb0020],[@bb0025]\], plasmid DNA (pDNA) \[[@bb0030],[@bb0035]\], messenger RNA (mRNA) \[[@bb0040],[@bb0045]\], and complexes containing guide RNA (gRNA) as part of gene editing approaches \[[@bb0050],[@bb0055]\].

Using nucleic acids therapeutically *in vivo* is challenging because of their unfavorable physicochemical characteristics, such as negative charge and relatively large size, which prevents their efficient uptake into cells \[[@bb0060]\]. In addition, nucleic acids are susceptible to degradation by nucleases in the circulation, suffer from rapid renal clearance, and induce immunostimulatory effects via pattern recognition receptors, resulting in adverse effects \[[@bb0065]\]. Therefore, the clinical translation of nucleic acid therapeutics has been dependent on chemical modifications and advanced delivery technologies to improve nucleic acids' stability, promote their target tissue accumulation, enable their cellular internalization, and increase their target affinity \[[@bb0070]\].

Lipid nanoparticle (LNP) systems are currently one of the most sophisticated non-viral gene delivery technologies enabling gene therapies \[[@bb0075]\]. Decades of designing lipid-based delivery systems for small molecule therapeutics \[[@bb0080]\] has driven efforts in adapting LNP technology for nucleic acid delivery \[[@bb0085],[@bb0090]\], particularly following the discovery of RNA interference (RNAi) \[[@bb0095],[@bb0100]\]. These efforts included systematically optimizing all LNP components for efficient gene silencing and incorporating siRNA payload modification and chemistry \[[@bb0105],[@bb0110]\], polyethylene glycol (PEG) lipids \[[@bb0115], [@bb0120], [@bb0125], [@bb0130]\], helper lipids \[[@bb0135],[@bb0140]\], and, particularly, ionizable cationic lipids \[[@bb0145], [@bb0150], [@bb0155]\].

In 2018, these developments culminated in the approval of Onpattro® (patisiran), the first RNAi drug, for treating hereditary amyloidogenic transthyretin (ATTRv) amyloidosis \[[@bb0160],[@bb0165]\]. This systemic disease, which generally presents as progressive neuropathy, is caused by mutations in the gene encoding the transthyretin (TTR) protein, resulting in amyloid fibril deposition in multiple organs \[[@bb0170]\]. Onpattro® relies on LNP technology for efficient TTR siRNA delivery to hepatocytes following systemic infusion, inhibiting mutant TTR protein production and subsequent fibril formation.

In this review, we provide an overview of the lipid nanotechnology-mediated gene regulation approaches in the liver for treating various diseases. First, we describe the liver's microanatomy and how its cell subtypes affect LNP accumulation and clearance. Second, we discuss design criteria and production methods \[[@bb0175],[@bb0180]\] for intravenously-administered LNPs delivering nucleic acid therapeutics to the liver. Finally, we highlight the (pre)clinical development of LNP-based genetic drugs for treating genetic liver diseases, hepatocellular carcinoma (HCC), and infections.

Of note, readers are referred to several excellent reviews covering other clinically relevant liver-targeted nucleic acid therapeutics, such as ASOs \[[@bb0015]\], N-acetylgalactosamine (GalNAc)-siRNA conjugates \[[@bb0020]\], or adenovirus-associated vectors \[[@bb0030],[@bb0035]\].

2. Liver microanatomy {#s0010}
=====================

With more than 500 functions ranging from metabolism (*e.g.* of lipids, carbohydrates, or amino acids) and protein secretion (*e.g.* hemostasis factors, plasma proteins, or hormones) to immune responses, the liver is one of the most vital organs \[[@bb0185]\]. Hundreds of hepatic disorders affect millions of people globally, with significant personal and systemic costs \[[@bb0010],[@bb0190]\]. In order to treat such diseases and develop relevant therapeutics, it is crucial to understand the liver's microanatomical and subcellular features.

The liver is divided into functional subunits called hepatic lobules. Nutrient and oxygen-rich blood from the portal vein and the hepatic artery traverse the lobules to the central vein ([Fig. 1](#f0005){ref-type="fig"} ), resulting in LNP exposure to scavenger cells within the liver. Liver sinusoidal endothelial cells (LSECs) line the sinusoidal vessels, while liver-resident macrophages, *i.e.* Kupffer cells, are localized within the hepatic sinusoids. Hepatocytes, the most prominent cell type and a key cell type for many diseases, are stationed behind the space of Disse \[[@bb0195],[@bb0200]\].Fig. 1Structure of liver lobules. The hepatic lobule is the liver's functional unit. Blood from the portal vein and the hepatic artery traverse the lobules to the central vein. Bile canaculi transport bile from the liver to the gut. Various metabolic pathways distribute along the porto-central axis of a liver lobule. GS, glutamine synthesis; Cho, cholesterol synthesis. Liver sinusoidal endothelial cells (LSECs) line the hepatic blood vessels, while liver-resident macrophages, *i.e.* Kupffer cells, are localized within the hepatic sinusoids. Hepatocytes are located behind the space of Disse with a sinusoidal (basolateral) membrane towards blood circulation. Figure adapted from Mosby *et al.* \[[@bb0240]\]Fig. 1

2.1. Cell types within the liver microenvironment {#s0015}
-------------------------------------------------

The term "liver gene therapy" is often used to unilaterally describe all gene therapy approaches for treating diseases originating in hepatocytes. Although hepatocytes are the most prominent cell type within the liver, several other cell types can interact with nanoparticles and affect their performance \[[@bb0205], [@bb0210], [@bb0215], [@bb0220]\]. It is therefore recommended that scientists expand their LNP studies to include single cell quantification rather than the whole liver. Every liver lobule comprises parenchymal (*i.e*. hepatocytes) and non-parenchymal liver cells (*i.e*. LSECs and Kupffer cells). In addition to these three major cell types, the liver consists of several other cell populations. A recent study revealed 20 discrete cell types ranging from stellate cells (also known as Ito cells) and cholangiocytes to immune cells such as B, T, or NK-like cells \[[@bb0225]\]. The human liver cell atlas revealed additional subtypes within the liver microenvironment \[[@bb0230]\]. The most relevant cell types and their implications for LNP-based gene therapy are discussed in the next sections, following the particle's journey in the body after systemic administration \[[@bb0235]\].

Following intravenous injection, LNP-siRNA systems (composed of CLinDMA:Cholesterol:PEG-DMG; 50:44:6 mol%) accumulate in all major liver cell types (*i.e.* Kupffer cells, LSECs, and hepatocytes) in a time- and dose-dependent manner, as demonstrated by Shi *et al.* \[[@bb0245]\]. When LNP-siRNA were administered at 0.3 mg siRNA/kg, similar siRNA amounts were detected in Kupffer cells and hepatocytes. Doses of 1 mg/kg to 9 mg/kg siRNA delivered 50% to 83%, respectively, to hepatocytes. At 30 minutes post injection, LNPs were mainly localized in the space of Disse, whereas 2 hours post injection LNPs accumulated in hepatocytes. siRNAs delivered to Kupffer cells and LSECs were inactive, but delivery to hepatocytes resulted in efficient gene silencing. A similar intrahepatic distribution has recently been described for LNP-DNA barcode systems (composed of MC3 or cKK-E12) by Sago *et al.* \[[@bb0250]\]*.* However, direct comparison of datasets carried out with different LNP systems, including variations in the lipid composition, ionizable lipid, lipid-nucleic acid ratios, and nucleic acid type must be assessed with caution. At a dose of 0.3 mg DNA /kg, LNPs accumulated in all three major liver cell types, with higher doses in Kupffer cells and hepatocytes than endothelial cells. In sharp contrast, gene expression following LNP-mediated mRNA delivery demonstrated an inverse hierarchy among hepatic cells: endothelial cells \> Kupffer cells \> hepatocytes. Higher LNP doses corresponding to 1 mg/kg mRNA shifted expression slightly towards hepatocytes while keeping the same pattern. Transfection of all major liver cell types with equal potency was recently demonstrated for LNP-mRNA systems (composed of branched-tail 306O~i10~) at a dose of 2 mg RNA/kg by Hajj *et al.* \[[@bb0255]\]*.*

Indeed, targeting the right cell type with the right dose is crucial to developing effective therapeutics. It should be noted that the LNP compositions described in these preclinical studies deviate from those used in the clinic (except for MC3-based LNPs). Systematic studies are therefore needed to improve our fundamental understanding of LNPs\' *in vivo* behavior. Rigorous control of physicochemical LNP characteristics such as size distribution, zeta potential, and entrapment will be crucial to assess the intrahepatic distribution of a single LNP composition with different payloads.

### 2.1.1. Kupffer cells -- Main phagocytotic center within the body {#s0020}

Following intravenous injection, liver-resident macrophages, *i.e.* Kupffer cells, are the first hepatic cells to interact with LNPs ([Fig. 1](#f0005){ref-type="fig"}). These phagocytic cells are part of the mononuclear phagocyte system (MPS), also known as the reticuloendothelial system (RES). They comprise 80% of the entire macrophage population within the body, illustrating their importance in host defense and LNP elimination \[[@bb0260]\].

Three major elimination pathways have been described \[[@bb0280]\]. First, negatively charged LNP systems are recognized by class A scavenger receptors (SR-A) expressed primarily on Kupffer cells resulting in rapid clearance \[[@bb0205],[@bb0285],[@bb0290]\]. Second, mannose- and fucose-type receptors can be leveraged to selectively target LNP systems to Kupffer cells. Third, LNP opsonization by serum proteins results in MPS sequestration. Complement factors (*e.g.* C3b or C1q) and serum opsonins such as fibrinogen can coat LNPs with unfavourable characteristics including large size, high surface charge, or lack of PEGylation \[[@bb0295], [@bb0300], [@bb0305]\]. Several research groups have explored strategies to prevent Kupffer cell clearance in order to redirect LNPs to hepatocytes. Transient Kupffer cell depletion using clodronate-loaded liposomes or by knocking out the endocytic Caveolin1 gene are efficient methods in a research setting \[[@bb0205],[@bb0215]\]. However, the clinical utility of such approaches is limited.

### 2.1.2. Liver sinusoidal endothelial cells -- Restricting hepatocyte access {#s0025}

LSECs are located in close proximity to Kupffer cells and play important roles in sequestering LNPs and restricting access to hepatocytes \[[@bb0310]\]. Many structural and functional features have been elucidated by Braet and Wisse \[[@bb0270],[@bb0315], [@bb0320], [@bb0325], [@bb0330], [@bb0335]\]. LSECs line the hepatic sinusoids and form pores, so-called fenestrations, that are clustered in sieve plates ([Fig. 2](#f0010){ref-type="fig"} ). Endothelial fenestrae range from 50 to 200 nm in diameter and differ between species ([Table 1](#t0005){ref-type="table"} ). Therefore, liver fenestrae physically restrict circulating LNPs' access to the perisinusoidal space and thus limit cellular interactions with hepatocytes according to size. Several research groups have investigated using pore-opening substances to modulate fenestrae size with limited success \[[@bb0320]\]. In addition to their structural characteristics, LSECs have high endocytic activity. A number of scavenger receptors, including stabilin-2, can efficiently sequester anionic nanoparticles \[[@bb0340]\].Fig. 2Liver sinusoids. (A) Cross section of a hepatic sinusoid. Liver sinusoidal endothelial cells form clustered fenestrations also known as sieve plates \[[@bb0265]\]. Reproduced with permission. Copyright 2009 American Physiological Society (B) Distribution of sinusoidal fenestrae size in healthy humans. Average diameter of endothelial fenestrae is 107 ± 1.5 nm. Adapted from Wisse *et al.* \[[@bb0270]\]. (C) Kupffer cell (KC) located within the hepatic sinusoid in close proximity to endothelial cells. Adapted with permission from UCSF Office of Medical Education \[[@bb0275]\].Fig. 2Table 1Comparison of liver fenestrations. Different species and strains have differently sized endothelial fenestrae in liver sinusoids. All studies used electron microscopy techniques to determine fenestrae diameters.Table 1SpeciesStrainsAverage diameter \[nm\]ReferenceHuman107 ± 1.5\[[@bb0270]\]RatSprague--Dawley161 ± 2.7\[[@bb0325]\]Wistar114 ± 4.7\[[@bb0315],[@bb0345]\]MouseC57BL/6\
BALB/c141 ± 5.4\
103 ± 23\[[@bb0350]\]\
\[[@bb0210]\]RabbitNew Zealand White103 ± 1.3\[[@bb0350]\]Fauve de Bourgogne108 ± 1.3\[[@bb0350]\]Dutch Belt124 ± 3.4\[[@bb0350]\]

### 2.1.3. Stellate cells -- Implications for LNP delivery {#s0030}

Hepatic stellate cells -- also known as Ito cells, vitamin A or lipid storage cells -- are localized within the perisinusoidal space of Disse \[[@bb0355]\]. In healthy human subjects, stellate cells are quiescent and function as vitamin A storage. However, liver damage and inflammatory processes induce stellate cell differentiation into a myofibroblast-like phenotype resulting in connective scar tissue production within the space of Disse \[[@bb0360],[@bb0365]\]. This pathophysiological process dramatically impairs the transendothelial transport of any substance from the systemic circulation to hepatocytes with major implications for nanoparticle-based nucleic acid therapeutics \[[@bb0370],[@bb0375]\].

### 2.1.4. Hepatocyte -- The key target for hepatic gene therapy {#s0035}

Hepatocytes, comprising 70-80% of the total liver cell population, are the most relevant hepatic target cell type for nucleic acid therapeutics ([Fig. 1](#f0005){ref-type="fig"}). Owing to their broad range of functions, hepatocytes play a key pathogenic role in many disorders ([Table 2](#t0010){ref-type="table"} ). Hepatocytes are highly differentiated with a sinusoidal (basolateral) membrane towards the blood circulation and an apical membrane towards bile canaliculi. The sinusoidal membrane with its microvilli exhibits surface receptors important for LNP recognition. The most important receptors for LNP-nucleic acid are the low-density lipoprotein receptor (LDLR) and asialoglycoprotein receptor (ASGPR) \[[@bb0380]\]. Within a healthy liver, hepatocytes are postmitotic (*i.e.* non-dividing cells) with an average life span of up to 6 months.Table 2Highlighted diseases originating in hepatocytes. Hepatocytes play major roles in various liver diseases including genetic disorders, infections, and cancer. Selected diseases are listed in order of their prevalence (from high to low), along with their pathophysiology, symptoms, current symptomatic treatments, and prevalence. Adapted with permission from Witzigmann *et al*. \[[@bb0385]\]Table 2DiseasePathophysiologyTypical symptomsSymptomatic treatmentPrevalence \[[@bb0390]\]Ref.**Genetic Disease (without parenchymal damage)**Hemophilia disorders (*e.g.*, Hemophilia B)Factor IX deficiency\
\[other coagulation factor mutations A and C\]Blood clotting disorder, hemorrhage*i.v.* infusion of coagulation factor1:20,000\[[@bb0395],[@bb0400]\]Urea cycle disorders (*e.g.*, OTC deficiency)Ornithine transcarbamylase (OTC) deficiency\
\[many other deficiencies such as Argininosuccinate synthetase (ASS; Citrullin-aemia), N-acetyl glutamate synthetase (NAGS), Carba-moylphosphate synthetase (CPS), Arginase (ARG)\]Hyperammo-nemia; neuro-logical damageNitrogen scavenger therapy, hemodialysisOTC: 1:80,000\[[@bb0405],[@bb0410]\]Familial Hyperchol-esterolemia (*e.g.*, LDL receptor related)LDL receptor protein mutation \[also ApoB or PCSK9 mutations\]Coronary artery diseaseStatins, LDL apheresisHomozygous \<1:100,000\
Hetero: 1:500\[[@bb0415],[@bb0420]\]TTR Familial amyloid polyneuropathy (FAP)Transthyretin mutation - deposition of insoluble proteinNeurodegene-ration, poly-neuropathySmall molecule drugs (tafamidis)\< 1:100,000, \> in some countries\[[@bb0425],[@bb0430]\]Thrombotic disorders (*e.g.*, Protein C deficiency type 1)Thrombotic disease caused by PROC gene mutation \[also other inherited thrombophilias\]Risk of thrombosisThrombo-embolism, protein C substitution1:500,000--750,000\[[@bb0435],[@bb0440]\]Primary hyperoxaluria type 1Alanine glyoxylate aminotransferase mutationCalcium oxalate accumulation, kidney damageHigh fluid intake, kidney trans-plantation1:333,000--1,000,000\[[@bb0405],[@bb0445]\]Bilirubin metabolism disorders (*e.g.*, Crigler-Najjar syndrome 1)Uridine diphosphate glucuronosyltransferase (UGT1A1) deficiency - impairment of bilirubin conjugationNeurological damage; kern-icterus (bilirubin encephalopathy)Phototherapy (10--12h per day); Plasma exchange\< 1:1,000,000\[[@bb0450],[@bb0455]\]**Genetic Disease (with parenchymal damage)**α1-antitrypsin deficiencyMutations in the SERPINA1 gene; deficiency in protease inhibitor for neutrophil elastaseLung and liver damageAugmentation;\
replacement therapy1--5:10,000\[[@bb0460],[@bb0465]\]Wilson´s diseaseCopper-transport P-type ATPase deficiency, Copper accumulationLiver and neuro-logical damageCopper complexation1:30,000-- 100,000 individuals\[[@bb0470],[@bb0475]\]Tyrosinemia disorders (*e.g.*, Tyrosinemia type 1)Fumarylacetoacetate hydrolase (FAH) deficiency - lack of tyrosine degra-dation \[other types with enzyme deficiency in tyrosine metabolism\]Hepatomegaly, liver and kidney dysfunctionNitisinone (inhibition of tyrosine degradation)1:100,000\[[@bb0480],[@bb0485]\]Iron overload disorder (*e.g.*, Hereditary hemo-chromatosis type 1)HFE enzyme deficiency\
\[other iron dysregulation; Type 2: HFE2 or HAMP (hepcidin); Type 3: TFR2 (transferrin receptor 2); Type 4: SLC40A1 (ferroportin)\]Liver cirrhosis, insulin resistancePhlebotomy, iron-chelatingType 1: \>1:1,000\
Type 2/3/4:\
\< 1 : 1,000,000\[[@bb0490],[@bb0495]\]Glycogen storage diseases (GSD) (*e.g.*, Pompe´s disease)Various types of enzyme deficiencies in glycogen synthesisHepatomegaly, hypoglycemiaTreatments depend on type1:50,000--1,000,000\[[@bb0500],[@bb0505]\]**Cancer**Hepatocellular Carcinoma (HCC)Chronic liver inflammation - cirrhosis - HCCLiver damage, liver cancerCurative or palliative treatment16:100,000 and\
\> 700,000 new cases per year\[[@bb0510], [@bb0515], [@bb0520]\]**Viral Infections**Hepatitis BHepatitis B Virus (HBV) infectionLiver damage, cirrhosis, HCCInterferon α, nucleos(t)ide350 million chronic carriers\[[@bb0525], [@bb0530], [@bb0535], [@bb0540]\]Hepatitis CHepatitis C Virus (HCV) infectionLiver damage, cirrhosis, HCCInterferon α, protease inhibitors180 million chronic carriers\[[@bb0525],[@bb0545]\]

2.2. (Patho)physiological factors affecting hepatic gene therapy {#s0040}
----------------------------------------------------------------

Many factors can alter LNP accumulation and clearance. The following sections detail important (patho)physiological factors affecting intrahepatic LNP distribution.

### 2.2.1. Metabolic and cellular liver zonation {#s0045}

An often-overlooked challenge in hepatic gene therapy is metabolic and cellular liver zonation, a phenomenon that separates various pathways along the porto-central axis of a liver lobule. First, some genetic disorders manifest in periportal or perivenous hepatocytes \[[@bb0550],[@bb0555]\]. Second, metabolic zonation can vary among species and during development (infant versus adult). Third, different non-parenchymal cell subtypes within the liver microenvironment can affect LNP clearance \[[@bb0225]\]. All these factors impact LNP development and gene therapy outcomes.

[Fig. 1](#f0005){ref-type="fig"} details the liver microarchitecture and its major metabolic pathways. Metabolic liver zonation for glucose homeostasis, urea synthesis, carbohydrates, bile acids, or lipid metabolism has been discussed in several excellent reviews \[[@bb0550], [@bb0555], [@bb0560], [@bb0565]\]. Advancements in omics and single-cell techniques are continuously elucidating new cell subtypes and improving our understanding of liver zonation \[[@bb0225],[@bb0550]\]. As illustrated, ureagenesis is restricted to periportal hepatocytes, while most intravenously injected nucleic acid therapeutics predominantly target perivenous cells. Bell *et al.* demonstrated a zonation bias for transducing hepatocytes in different species and at different ages \[[@bb0570]\]. While transgene expression in adult mice and dogs was predominantly pericentral following viral transduction, the expression pattern in cynomolgus and rhesus macaques was mainly periportal. In contrast, newborn mice and infant rhesus macaques showed equal distribution. This bias has important implications for gene therapies, *e.g.* to correct ornithine transcarbamylase (OTC) deficiency \[[@bb0575]\]. Further studies are warranted to investigate such phenomena for LNPs.

Improved LNP design might facilitate gene expression within the target zone along the porto-central axis. A recent study by Sago *et al.* investigated whether non-parenchymal cell subtypes differentially interact with LNPs and thereby affect their clearance \[[@bb0250]\]. Interestingly, LNPs' intra-hepatic and sub-cellular distribution varies with lipid composition. Periportal endothelial cells (CD32^Low^) sequestered cKK-E12-based LNPs more efficiently than central venous endothelial cells (CD32^High^), most likely due to the blood flow direction and the order of exposure. LNPs composed of MC3 had similar levels of delivery to both periportal and central venous endothelial cells. In contrast, clearance of MC3-based LNPs was significantly higher in tolerogenic, M2-like Kupffer cells (CD74^Low^) as compared to inflammatory, M1-like Kupffer cells (CD74^High^). Recent findings emphasize this preferential nanoparticle uptake by M2-type macrophages, with a clear hierarchy among the different phenotypes (M2c \> M2 \> M2a \> M2b \> M1) \[[@bb0580]\]. It is tempting to speculate that differences in apparent pKa values and structural LNP characteristics resulted in distinct biomolecular coronas preferentially redirecting LNPs to different cell subtypes. However, precise mechanistic studies are needed to elucidate underlying phenomena and clearance by all intermediate phenotypes \[[@bb0585]\].

Sleyster *et al.* demonstrated that periportal Kupffer cells are more abundant and have higher endocytic and lysosomal activity than perivenous Kupffer cells \[[@bb0590]\]. These results demonstrate that whole-tissue (entire liver) analysis should be replaced by dissociated single cell-based techniques.

### 2.2.2. Pathophysiological remodelling {#s0050}

Liver disease progression results in pathological remodelling including microanatomical or target receptor alterations that could affect nanoparticle delivery and sequestration. Firstly, liver infections or metabolic disorders can lead to chronic cell damage and cell activation. This can result in liver fenestrae re-arrangement or fibrotic material deposition by activated stellate cells within the perisinusoidal space. Thus, LNP transport to hepatocytes is inhibited, as is access to the key target cell for most gene therapies \[[@bb0595]\]. Hepatic inflammatory processes can also enhance hepatic nanoparticle sequestration by Kupffer cell activation \[[@bb0580]\]. Secondly, downregulation of surface receptors crucial for LNP binding decreases gene delivery efficiency. For example, two independent studies have demonstrated lowering of ASGPR expression during HCC progression (according to the Barcelona Clinic Liver Cancer staging) \[[@bb0600],[@bb0605]\]. This has serious implications for liver cancer interventions using ASGPR-targeting approaches. Thirdly, variations in serum proteins, such as apolipoprotein E (ApoE), are known to mediate specific LNP binding and might affect efficacy. A recent study investigated the effect of ApoE polymorphisms in patients with ATTRv amyloidosis treated with Onpattro® \[[@bb0610]\]. Niemietz *et al.* revealed that efficacy is independent of the ApoE genotype but that ApoE downregulation reduces efficacy. All the aforementioned pathophysiological alterations affect specific cell binding and could potentially limit therapeutic outcomes. Therefore, diagnostic tools to stratify patients for LNP-based gene therapy offer interesting possibilities \[[@bb0615]\].

3. Designing LNPs for gene regulation in the liver {#s0055}
==================================================

The fundamental LNP design parameters for nucleic acid delivery are based on those established for small molecule liposomal formulations. These parameters include appropriate particle size (for efficient terminal sterile filtration and hepatic delivery), long-term stability in storage, optimized payload release rates to produce a therapeutic effect, robust and scalable manufacturing processes, and efficient entrapment. In applying these requisites to nucleic acid delivery systems, it became obvious that additional lipid components and functionalities were required beyond those used to compose small-molecule carriers. The very first nucleic acid formulations, containing only phosphatidylcholine and cholesterol, demonstrated that nucleic acid entrapment within a particle was feasible, but the entrapment efficiency was poor \[[@bb0620],[@bb0625]\]. Subsequent development of the cationic lipid 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) showed that ionic interactions between the lipids and payload can dramatically increase entrapment efficiencies and intracellular delivery. Toxicity issues, resulting from the cationic lipids' permanent positive charge and non-biodegradable nature, plagued these initial lipoplex-like formulations \[[@bb0630]\]. Through additional formulation development, and manufacturing process optimization, it was determined that LNP systems required four components: ionizable cationic lipids, phospholipids (typically phosphatidylcholine), cholesterol, and PEG-lipids. The role of each component, the evolution of the composition, and the manufacturing processes are discussed in the following sections.

3.1. Ionizable cationic lipids {#s0060}
------------------------------

To date, a vast number of ionizable cationic lipids covering a wide range of structures have been developed ([Fig. 3](#f0015){ref-type="fig"} ), yet they all share a few aspects: (1) The headgroups contain tertiary amines that become protonated under acidic pH and typically are uncharged (or zwitterionic) at neutral pH; (2) The lipid tails contribute to making the molecule sufficiently hydrophobic to promote incorporation into a nanoparticle during formation; and (3) The protonated lipids generate structures that help elevate propensity for membrane fusion in acidified endosomes following internalization by the target cell. In addition to these similarities, the various lipids' performed functions are essentially identical. As the pH of the environment dictates the headgroup protonation, LNP are prepared in an acidic aqueous buffer (*e.g.* pH 4) that promotes the charge interaction between the ionizable cationic lipid and the anionic nucleic acid. Subsequent buffer exchange into isotonic and pH-neutral buffer generates the final LNP suspension with a near net-neutral surface charge. This uncharged state is critical to preventing immune responses upon intravenous administration and facilitates delivery to hepatocytes \[[@bb0630]\]. The next function is to maintain a positive charge in the acidified endosome and promote membrane fusion to allow cytosolic delivery of the nucleic acid. This fine balance of positive charge at acidic pH and neutral charge at physiological pH is the result of substantial efforts towards optimizing the ionizable lipid for *in vivo* nucleic acid delivery.Fig. 3Ionizable cationic lipids or lipid-like materials (lipidoids) enabling gene therapy in the liver. Various lipid-like materials have been developed for nucleic acid delivery. The headgroups contain tertiary amines which become protonated under acidic pH and have typically no charge at neutral pH. The lipid tails contribute to making the molecule sufficiently hydrophobic to promote incorporation into LNPs while endowing either stabilizing or destabilizing properties. The above lipids are classified into three broad categories: (i) ionizable cationic lipids such as DLinDMA \[[@bb0665]\], DLin-KC2-DMA \[[@bb0150]\], and DLin-MC3-DMA \[[@bb0155]\]; (ii) lipidoids like cKK-E12 \[[@bb0670]\] and C12-200 \[[@bb0145]\]; and (iii) next- generation lipids including the biodegradable molecules L319 \[[@bb0650]\], TT3 \[[@bb0675]\], and ssPalmE \[[@bb0680]\] as well as lipids from proprietary libraries belonging to Acuitas (A9) \[[@bb0685]\] and Moderna (L5) \[[@bb0690]\].Fig. 3

One of the first tested ionizable lipids, known as dioleyl-dimethylaminopropane (DODMA), contained oleyl lipid tails (C18:1) conjugated to the dimethylamino-propyl headgroup through ether linkers. Using the *molecular shape hypothesis* as a guiding principle \[[@bb0635]\], the three components of these lipids (headgroup, linker, and tails) were systematically studied to determine optimal characteristics for each. The molecular shape hypothesis describes the macrostructure obtained upon hydration of a lipid with specific geometries. More specifically, lipids containing tails with larger cross-sectional areas than the lipid headgroups result in H~II~ phases or inverted micelles; comparatively, when the cross-sectional area of the tails is similar to that of the head group (resulting in a cylindrical geometry), the lipids tend to from bilayers. Comparing different lipid tail-unsaturation suggested that the linoleyl chains (DLinDMA) provide optimal particle internalization and potential to generate membrane-destabilizing H~II~ phases \[[@bb0640]\]. Subsequent studies focused on improving the headgroup and linkers. Replacing the ether linkers in DLinDMA with esters resulted in a lipid, DLin-DAP, with substantially reduced potency \[[@bb0150]\]. Further studies suggested that ester bond degradation within the acidified endosome contributed to efficacy loss \[[@bb0645]\]. Simultaneously, a series of headgroup modified lipids were tested, and DLin-KC2-DMA was designed with vastly higher potency than DLinDAP and DLinDMA ([Fig. 3](#f0015){ref-type="fig"}) \[[@bb0150]\]. Further modifications and screening led to the development of DLin-MC3-DMA ([Fig. 3](#f0015){ref-type="fig"}) \[[@bb0155]\], used in the clinical formulation, Onpattro®, and now considered the gold-standard for ionizable cationic lipids.

Although several screening methods for ionizable lipids have been devised, the critical potency test for hepatic targets was the *in vivo* model for hepatic gene silencing; the Factor VII (FVII) model provided a modestly high-throughput approach \[[@bb0145]\]. FVII is a serum protein produced by hepatocytes in the liver and secreted into the circulation. Its short half-life enables gene silencing assessment on the protein level within a short timeframe. It is important to stress that FVII-knockdown screens specifically identify LNPs that target hepatocytes and ignore all other hepatic cell types. LNP containing siRNA against murine FVII were intravenously administered over a dose range of 0.001-10 mg siRNA per kg body weight and circulating FVII levels were determined by chromogenic assay 24 hours later. The metric used to compare formulations was the effective dose required to achieve 50% gene silencing (ED~50~), and DLin-MC3-DMA (MC3) was determined to be the most potent ionizable cationic lipid for LNP-based gene silencing. The potency improvements cover the range of DLinDAP with an ED~50~ of \~20 mg/kg, while that for MC3 was 0.005 mg/kg in mice \[[@bb0150],[@bb0155]\].

Further developments focused on lipid biodegradability to reduce potential toxicity, immunogenicity, and other adverse effects \[[@bb0650]\]. The design parameters for these lipids included high *in vivo* transfection efficiency, increased ability to be metabolized, and no generation or accumulation of toxic metabolites. One approach incorporates an ester linkage, which can be easily hydrolyzed by intracellular esterases or lipases, into the lipid tail. For example, Maier *et al.* demonstrated that including ester bonds between carbons 9 and 10 in the linoleyl chain (named L319) resulted in similar potency as the MC3-lipid but almost complete elimination over 24 hours \[[@bb0650]\]. The ester bond position was critical to the function and elimination rate. When positioned closer to the head group, these bonds affected the lipid pKa, and thus its gene silencing potency. When positioned further away from the head group, the lipids persisted in the liver for extended periods of time. In another example, Shirazi *et al*. detailed the synthesis of degradable multivalent cationic lipids containing a disulfide bond between the head and tail groups, resulting in improved cell viability *in vitro* \[[@bb0655]\]. Akita *et al*. also synthesized a series of disulfide bond containing lipid-like materials incorporating alpha tocopherol as the lipid tails (ssPalmE) \[[@bb0660]\].

3.2. Helper lipids - phospholipid and cholesterol {#s0065}
-------------------------------------------------

Two LNP components -- phospholipids and cholesterol -- have generally been seen to promote formulation stability \[[@bb0695]\]. Although that evidence is largely anecdotal in the LNP context, phospholipids such as DSPC, with strong bilayer-forming properties and high phase transition temperatures, help increase membrane rigidity and reduce membrane permeability. While the role of cholesterol remains largely unclear in the context of nucleic acid delivery systems, cholesterol-deficient particles can sequester cholesterol while in circulation, leading to potentially destabilizing effects \[[@bb0700]\]. This sequestration process is largely driven by the exchange of cholesterol away from the plasma membrane of peripheral tissues into lipoproteins in circulation followed by equilibration into circulating liposomes. Recently, Harashima and colleagues studied cholesterol-free LNP-siRNA systems (only composed of the ionizable cationic lipid CL15H6, phospholipid, and PEG-lipid) and they observed decreased potencies in the presence of serum likely due to particle instability as a result of cholesterol accumulation \[[@bb0705]\].

Two studies suggested that the amount of cholesterol typically formulated into an LNP is larger than what can be stably retained in LNPs. More recently, it was determined that \~30-40 mol% helper lipid is required to efficiently entrap siRNA within LNPs, providing additional insight into the role of these helper lipids \[[@bb0135]\]. The helper lipids serve to space-out ionizable lipids to achieve a membrane surface charge of approximately +1 per nm^2^ (siRNA has a surface charge of approximately -1 per nm^2^).

Limited information is available on the role of helper lipids for LNP activity. However, some evidence has suggested that the replacement of DSPC with DOPE in lipidoid-based LNPs improves mRNA delivery *in vivo* \[[@bb0710]\]. For LNP-pDNA formulations, certain unsaturated phosphatidylcholines (*i.e.*, SOPC and DOPC) improved the LNP activity over DSPC in the presence of FBS *in vitro* \[[@bb0140]\]. DOPE-containing LNP-pDNA systems showed best activity in murine serum suggesting a potential role of helper lipids in modifying the LNP surface affinity to distinct apolipoprotein subtypes. An additional role of cholesterol in LNP systems was recently investigated \[[@bb0715]\]. Incorporating oxidized cholesterols such as 20α-OH redirected LNP-mRNA systems from hepatocytes to hepatic endothelial cells and Kupffer cells. Although the mechanism of modifying LNP tropism remained elusive, formation of different protein coronas and/or recognition by scavenger receptors expressed on hepatic RES (such as scavenger receptor class B type I as binding site for oxidized LDL) might have resulted in redirection of LNPs \[[@bb0720],[@bb0725]\].

3.3. PEG-lipid {#s0070}
--------------

The final LNP component, the PEG-lipid, is engineered to perform two specific functions. First, PEG-lipids incorporate into the emerging nanoparticle during LNP formation. As LNP systems do not contain an aqueous core, PEG-lipids reside almost exclusively on the LNP surface, and their concentrations control particle size \[[@bb0730]\]. Both the PEG molecular weight as well as the molar percentage of PEG-lipid affect the characteristics of lipid-based particles \[[@bb0735], [@bb0740], [@bb0745]\]. Specifically, as the PEG-lipid is increased from 0.25 mol% to 5 mol%, a reduction in LNP size is observed from \~120 nm to 25 nm, but further increases to PEG-content do not modify particle size \[[@bb0120],[@bb0735]\]. Second, they improve the shelf-stability by creating a steric barrier that extends away from the surface of the LNP, thereby preventing particle aggregation and improving *in vivo* circulation lifetimes. However, for transfection purposes, PEG-lipids have an established inhibitory effect \[[@bb0750],[@bb0755]\]. Based on the hypothesized mechanism of LNP function, the nanoparticle requires an intricate balance between stability in storage and circulation, and instability within the cell to support intracellular delivery \[[@bb0760]\]. *Diffusible* PEG-lipids helped stabilize particles while enabling intracellular delivery \[[@bb0125],[@bb0755]\]. These lipids are composed of acyl chains that are 14-carbons in length and can dissociate rapidly from the LNP in the circulation \[[@bb0765]\]. Two hours post administration, only 20% of the injected PEG-lipid is associated with the LNP. In contrast, PEG-lipids with 18-carbon acyl chains, incorporate into the LNP and do not dissociate from the particle in the circulation. At high concentrations, these PEG-lipids can contribute to extending circulation half-life (from \< 30 minutes for diffusible PEG-lipid to \> 2 hours) \[[@bb0115],[@bb0765]\]. However, LNPs designed to target hepatic disorders do not require a prolonged circulation lifetime due to the liver's natural ability to sequester nanoparticles. Therefore, diffusible PEG-lipids are ideal for such applications.

3.4. Manufacturing {#s0075}
------------------

LNP production methods have evolved over time with certain processes gaining prominence. Rapid-mixing methods have gained favor for their decreased labour requirements as they combine nanoparticle formation and nucleic acid entrapment into a single step \[[@bb0770]\], and provide more homogenous nanoparticles. The first report of rapid-mixing was by Batzri and Korn, where an ethanolic lipid solution was rapidly injected into an aqueous solution to form liposomes \[[@bb0775]\]. Applying this method to nucleic acids involved combining pre-formed cationic liposomes with nucleic acids to produce lipoplexes \[[@bb0780]\]. More recently, a T-junction mixing chamber was used for two separate mixing steps \[[@bb0770]\]. The first mixing step brought together an ethanolic lipid stream with an acidic aqueous buffer containing nucleic acid at an equal flow rate (1:1 v/v mixing). This created metastable particles that were combined with aqueous buffer in a second mixing step (through the T-mixer) to dilute the ethanol content and stabilize the nanoparticles. To simplify this process into a single step, the mixing ratio was modified to 1 part ethanol and 3 parts aqueous. These rapid-mixing methods produce homogenous nanoparticles with entrapment efficiencies \> 90% and, importantly, have been proven to be fully scalable \[[@bb0165],[@bb0730],[@bb0785],[@bb0790]\].

3.5. Optimizing LNP characteristics {#s0080}
-----------------------------------

A number of recent studies have demonstrated that LNP systems accumulate in various cell types within the liver \[[@bb0245],[@bb0250],[@bb0715],[@bb0795]\]. Important physicochemical characteristics that modulate intrahepatic LNP distribution and activity are particle size, apparent pKa value (and resulting surface charge), and lipase sensitivity \[[@bb0795]\]. For clinical utility, it is also expected that these formulations display high entrapment efficiencies.

A recent study by Chen *et al.* investigated how LNP size (30 nm -- 120 nm) influences gene silencing in hepatocytes \[[@bb0765]\]. A clear hierarchy in gene silencing potency was observed with LNP-siRNA systems around 80 nm exhibiting maximum activity (78 nm \> 42 nm \> 38 nm \>\> 27 nm \> 117 nm). This LNP size optimum results from a combination of two factors: 1) smaller particles being less active (less stable and less fusogenic); and 2) larger particles (\>100 nm), not being able to access hepatocytes (limited by fenestrations). Sato *et al.* verified these results demonstrating significant reduction in hepatocyte gene silencing for LNP-siRNA sizes above the average liver fenestrae diameters \[[@bb0795]\]. Interestingly, similar gene silencing activity in LSECs was observed for LNP-siRNA sizes up to 200 nm. This suggests that LNP sizes between 120 nm to 200 nm could be used for LSEC targeting.

A key advance during the development of Onpattro® for hepatocyte gene silencing was identifying an optimized ionizable cationic lipid with an apparent pKa between 6.2 and 6.5 \[[@bb0085],[@bb0155]\]. Further increasing the pKa value to 7.15 resulted in improved gene silencing in LSECs \[[@bb0795],[@bb0800]\]. Incorporating ionizable cationic lipids exhibiting higher pKa values increased accumulation in the MPS, most likely due to scavenger receptor recognition \[[@bb0795]\].

The lipid sensitivity to phospholipase is another important factor modulating intrahepatic LNP distribution and activity. Three different lipases have been described including the lipoprotein and endothelial lipase in LSECs and the hepatic lipase in hepatocytes \[[@bb0805]\]. LNP-siRNA systems that incorporate ionizable cationic lipids that are sensitive to endothelial lipase (*e.g.* ester linkages between head and tail functions) have enhanced gene silencing in hepatocytes but exhibit significantly reduced activity in LSECs \[[@bb0795]\]. Co-treatment with lipase inhibitors or incorporating lipase-resistant ionizable cationic lipids can recover gene silencing in LSECs \[[@bb0795]\].

Based on microanatomical, subcellular, and (patho)physiological considerations, an ideal LNP for gene regulation in hepatocytes must satisfy the following design criteria: nanoparticle size \< 80 nm to efficiently pass through liver fenestrae and improve LNP stability, apparent ionizable cationic lipid pKa value around 6.4, near neutral surface charge to prevent sequestration by the MPS, and lack of immune stimulation and toxic effects. Achieving these and other criteria facilitating efficient nucleic acid entrapment and LNP formulation are detailed in the following section.

It is important to mention that upon intravenous administration LNPs adsorb serum proteins on their surface. Many, if not all, of the abovementioned physiochemical characteristics impart distinct properties to the LNPs which ultimately influence protein adsorption. This "*biomolecular corona*" covering nanoparticles significantly impacts systemic circulation and nano-bio interactions \[[@bb0810], [@bb0815], [@bb0820]\]. Efficient targeting and gene regulation in hepatocytes stems from the presence of ApoE in the corona of LNPs and enabled the success of Onpattro® \[[@bb0165],[@bb0380]\]. A recent publication suggested that the ionizable lipid composition plays a major role in the corona formed \[[@bb0825]\]. How the biomolecular corona can be leveraged to optimize targeting of different cell types within the liver microenvironment needs to be investigated.

4. Preclinical development and rationale for lipid nanotechnology {#s0085}
=================================================================

Research in the late 1980s focusing on *in vivo* pDNA delivery showed that in the absence of a delivery system, naked nucleic acid injected into the circulation rapidly broke down and the products accumulated in hepatic tissue \[[@bb0830]\]. As interest towards ASOs and siRNA grew, LNP compositions and production methods simply translated from plasmids to these shorter nucleic acids \[[@bb0835]\]. More recently, formulations have become sufficiently potent to support discovery and translation of mRNA therapeutics \[[@bb0840]\]. [Fig. 4](#f0020){ref-type="fig"} illustrates the different LNP-based treatments for hepatic diseases by silencing pathogenic genes, expressing therapeutic proteins, or correcting genetic defects. [Table 3](#t0015){ref-type="table"} highlights preclinical LNP-based hepatic gene therapy approaches.Fig. 4Therapeutic applications of LNPs enabling genetic drug delivery. LNPs can deliver siRNA, mRNA, DNA, or gene editing complexes, providing opportunities to treat hepatic diseases by silencing pathogenic genes, expressing therapeutic proteins, or correcting genetic defects. Following LNP internalization, nucleic acid therapeutics are released into the cytoplasm. DNA vectors require nuclear translocation to be active. Adapted with permission from Buck *et al.* \[[@bb0845]\]. Copyright 2019 American Chemical Society.Fig. 4Table 3Selected LNP-based nucleic acid therapeutics in preclinical development. LNPs can deliver siRNA, mRNA, DNA, or gene editing complexes, providing opportunities to treat hepatic diseases by silencing pathogenic genes, expressing therapeutic proteins, or correcting genetic defects.Table 3PayloadGene target/productLNP compositionCellular target / indicationAdministration routeModelReference**Gene silencing**siRNAFVIIDMAP-BLP / DSPC / cholesterol / PEG-DMG (50:10:(39.75 -- x):(0.25+x))Hepatocytes / ScreeningSubcutaneousC57Bl/6 mice\[[@bb0735]\]siRNAFVIIIonizable cationic lipid / DSPC / cholesterol / PEG-DMG\
40:10:40:10Hepatocytes / ScreeningIntravenousC57BL/6 mice\[[@bb0155]\]siRNATTRDLin-MC3-DMA / DSPC / cholesterol / PEG-DMG\
50:10:38.5:1.5Hepatocytes / ATTRv amyloidosisIntravenousCynomolgus monkeys\[[@bb0155]\]siRNAApoBDLinDMA / DSPC / cholesterol / PEG-C-DMA\
40:10:48:2Hepatocytes / HypercholesterolemiaIntravenousCynomolgus monkeys\[[@bb0665]\]  **Gene expression**mRNAanti-HIV-1 antibody VRC01Ionizable cationic lipid / PC / cholesterol / PEG-lipid (50:10:38.5:1.5)Hepatocytes / Passive immunotherapy against HIV-1IntravenousBALB/C mice\[[@bb1005]\]mRNALuciferase / Cre-recombinaseDOTMA/DOPE\
DOTMA/CholScreeningRetro-orbitalNMRI mice / Reporter mice\[[@bb1045]\]pDNALuciferaseCationic lipid/Chol-GALA/Malto-PEG6-C11\
30:40:30ScreeningIntravenousICR mice\[[@bb0870]\]  **Gene editing**sgRNA\
mRNATTR\
Cas9LP01 / DSPC / cholesterol / PEG-DMG\
45:9:44:2Hepatocytes / ATTRv amyloidosisCD-1 mice\
Sprague Dawley rats\[[@bb1030]\]sgRNA\
mRNAPCSK9\
Cas9BAMEAO16B / cholesterol / DOPE / DSPE-PEG2000\
16:8:4:1Hepatocytes / HypercholesterolemiaIntravenousC57BL/6\[[@bb1050]\]

4.1. DNA delivery for long-term gene therapy and barcoding technologies {#s0090}
-----------------------------------------------------------------------

Refining lipid-DNA complexes to more advanced formulations required additional lipids, and such nanoparticles were termed stabilized plasmid lipid particles (SPLP) \[[@bb0845],[@bb0850]\]. The composition of these formulations largely drew from those used for small molecule therapeutics and included about 6-8 mol% ionizable lipid at the expense of the phosphatidylcholine (*i.e.* DSPC). Delivery with SPLP systems showed no evidence of hepatic toxicities compared to the lipoplex-equivalent, which resulted in a 100-fold increase in serum ALT/AST levels \[[@bb0855]\]. These formulations were designed in a manner to promote accumulation at disseminated diseased sites (infection, inflammation, and solid tumors), requiring extended circulation residence times. With circulation half-lives nearing 7-8 hours, they induced reporter gene expression in tumor tissue, and substantially lower levels in the liver. However, as formulation development proceeded, it became clear that a limitation of non-viral technology was the inability to deliver nucleic acid into the nucleus of a target cell.

To address this issue, efforts have been made to increase nuclear targeting by including cell penetrating or nuclear localization sequence (NLS) peptides in the lipid formulations. These short, cationic peptides are thought to interact with the anionic DNA and enable nuclear translocation through nuclear core complexes. Initial studies using the Simian virus SV40 T antigen NLS peptide in a DOTAP/DOPE (50:50) liposome demonstrated improved nuclear targeting *in vitro* and up to a threefold increase in the plasmid-encoded luciferase signal \[[@bb0860]\]. Formulations utilizing the cell-penetrating peptide, octaarginine \[[@bb0865]\], or the recently identified non-peptide NLS \[[@bb0870]\], maltotriose, also demonstrated an increase in both nuclear targeting and gene expression *in vitro*. Maltotriose-incorporated liposomes also demonstrated higher hepatic luciferase expression levels *in vivo* compared to conventional DOTAP lipoplexes. Nevertheless, non-viral technology (without DNA modifications or specific nuclear targeting moieties) has generally been unsuccessful in transfecting non-dividing cells and in liver-specific applications but finds use in robust and safe transfection of neoplasms or developing tissues.

The ability to transfect dividing (liver cancer) cells was most recently highlighted in a study where LNP systems optimized for pDNA were found to yield potent transfection \[[@bb0140]\]. Starting with the formulation optimized for siRNA delivery containing MC3 and DSPC, Kulkarni *et al.* found that replacing the helper lipid and ionizable lipid with unsaturated lipids such as SOPC or DOPE and DLin-KC2-DMA, respectively, lead to much higher *in vitro* transfection of multiple liver cancer derived cell lines with little toxicity. This suggests that LNP systems, once optimized for DNA vector delivery, can not only find utility for protein expression, but potentially also in gene editing with CRISPR/Cas9-encoded plasmids for treating hepatic diseases.

While most DNA delivery applications have focused on gene therapy, a highly interesting application is employing DNA as barcodes for diagnostic and screening purposes \[[@bb0740]\]. Utilized as short fragments and each with a unique sequence, DNA barcodes allow for high-throughput, multiplexed *in vivo* screening to determine the biodistribution, uptake, and functional activity within the liver microenvironment (as outlined in section 2.2. and 3.5) \[[@bb0250],[@bb0715]\]. Notably, as a diagnostic tool, DNA barcodes have also been used for developing personalized cancer nanomedicines by co-loading them together with anticancer drugs into lipid nanocarriers. Utilizing this strategy, multiple anticancer medicines can be administered at sub-therapeutic doses and the most effective drug can subsequently be identified in the biopsies according to their barcode \[[@bb0875]\]. As only limited therapies are available for liver cancer, this methodology could well be used towards identifying effective and novel treatments for liver cancer. Although lipid calcium phosphate nanoparticles (LCPs) are beyond the scope of this review, in the context of liver cancer, it is relevant to note the work by Leaf Huang and colleagues demonstrating that LCP-based DNA delivery enables mitigation of liver metastasis \[[@bb0880], [@bb0885], [@bb0890]\].

4.2. siRNA for transient gene silencing {#s0095}
---------------------------------------

All procedures and compositions developed for DNA delivery readily translated into effective delivery systems for other nucleic acids \[[@bb0835]\]. siRNA only requires cytoplasmic delivery as all RNA-induced silencing complex (RISC)-related machinery is located in the cytosol. This quick translation resulted in demonstrating the first robust gene silencing in non-human primates (NHP) using nanoparticles known as stable nucleic-acid lipid particles (SNALPs) containing siRNA against apolipoprotein B (ApoB) \[[@bb0665]\]. Only twelve years later, Onpattro® was approved by the FDA for treating ATTRv \[[@bb0895]\].

In the early 2000s, the concept of modifying nucleic acids was largely applied to improving their cytoplasmic persistence to enable long-term knockdown (decreased siRNA turnover). As such, modified siRNAs were entrapped into LNP systems with the rationale that a delivery system was specifically required to increase siRNA's liver accumulation and intracellular quantity. This had to be achieved in a manner where the cost of raw materials and processing was offset by a potent formulation, *i.e.* a drastic reduction in material requirement made the formulation commercially viable. With LNP formulations containing DLin-MC3-DMA, murine data suggested that as little as 0.005 mg siRNA/kg body weight was required to achieve 50% gene silencing, with no observable toxicities. While alternative technologies such as siRNA-conjugates are also gaining prominence \[[@bb0020]\], the applicability of LNP technology for hepatic targets is quite clear. It should be noted that siRNA-conjugates require substantially higher doses (\~1 mg/kg, weekly subcutaneous administration) in order to achieve gene knockdown \[[@bb0900]\]. LNP-siRNA systems have shown utility in decreasing viral loads and virulence, various applications in hepatic oncology, and in metabolic liver disease treatment.

RNAi finds strong support in anti-viral applications where strict adherence to treatment regimens is critical to success. LNP-siRNA treatments can provide sustained knockdown for months leading to long-term viral gene suppression with a potential to eliminate certain viruses. One example is using LNP-siRNA as a therapeutic intervention for the Ebola outbreak in 2013, which resulted in almost 28,000 cases and 11,300 deaths \[[@bb0905]\]. LNP-siRNA formulations could be rapidly adapted to provide siRNA complementarity to the specific strain and showed that a combination of three siRNAs against the viral RNA synthesis genes suppressed the infection in non-human primates (NHP) \[[@bb0905]\]. Similarly, LNP-siRNA modification with GalNAc-conjugated PEG-lipids to specifically accumulate in hepatocytes (of chimeric mice with humanized livers) reduced Hepatitis B Virus (HBV) genomic DNA and antigens \[[@bb0910]\]. Other anti-viral LNP examples include those for hepatitis delta virus (co-infected with HBV) and hepatitis C virus \[[@bb0915],[@bb0920]\].

LNP-mediated siRNA delivery for hepatic oncology applications has largely focused on downregulating genes critical for cell cycle regulation, thereby inducing apoptosis. One example is LNP-siRNA against polo-like-kinase 1 (PLK1), which regulates multiple cell cycle progression stages. PLK1 is over expressed in multiple tumors including liver cancer and down-regulation has been successful as an intervention \[[@bb0925]\]. Similarly, simultaneous vascular endothelial growth factor (VEGF) and kinesin spindle protein (KSP) knockdown has been shown to inhibit proliferation in hepatocellular carcinoma and induce apoptosis \[[@bb0930]\]. Zhou *et al.* demonstrated that delivery of the small RNA let-7g inhibited tumor growth and dramatically extended survival in a *MYC*-driven genetic liver cancer tumor model \[[@bb0935]\].

Examples of LNP-siRNA delivery for liver-related metabolic disorders are plentiful. An interesting clinical observation was that loss-of-function mutations in proprotein convertase subtilisin/kexin type 9 (PCSK9) resulted in low cholesterol levels in circulation. This finding prompted the investigation into using siRNA to downregulate PCSK9 as a treatment for hypercholesterolemia. Murine and NHP studies showed that specific PCSK9 transcript lowering resulted in reversible and durable knockdown of PCSK9, apolipoprotein B (ApoB), and low-density lipoprotein associated cholesterol \[[@bb0940]\]. Similarly, in the first demonstration of RNAi in higher-order mammals, ApoB knockdown resulted in reduction of ApoB levels, serum cholesterol content, and LDL particle concentration in NHPs \[[@bb0665]\]. Other lipid-trafficking related targets include apolipoprotein C3 knockdown for hyperlipidemia \[[@bb0945]\], and angiopoietin-like 3 protein inhibition for hypertriglyceridemia \[[@bb0950]\].

Lastly, we discuss the specific case of Onpattro® (patisiran), an LNP-siRNA formulation targeting the *ttr* gene. TTR is a homotetrameric serum protein that is synthesized in hepatocytes and secreted into the systemic circulation (note similarity to FVII) \[[@bb0955]\]. When mutated, TTR deposits as amyloid fibrils in cardiac or peripheral nervous tissue resulting in multi-system failure including ocular, cardiovascular, nephropathy, gastrointestinal, and neuropathy (autonomic and peripheral sensorimotor) manifestations. TTR downregulation with LNP-siRNA is a powerful approach to treat this disease. Murine data suggested that at doses of 0.1 mg/kg siRNA, \> 85% liver *ttr* mRNA knockdown and TTR protein serum concentrations could be achieved \[[@bb0960]\]. Further testing in NHPs showed that an intravenous dose of 0.3 mg/kg every 4 weeks resulted in rapid and reversible knockdown, although serum levels increased two weeks after each administration. Increasing the dosing frequency to once every three weeks resulted in sustained and robust knockdown (\> 90%) following the third dose.

4.3. mRNA for gene expression and genome editing {#s0100}
------------------------------------------------

Introducing exogenous mRNA to induce a therapeutic effect has great potential for a variety of applications. The true benefits of LNP technology for gene regulation in the liver are best highlighted with mRNA. Specifically, mRNA requires a delivery system as modifications to the nucleotides alone have not proven successful in meeting the potency requirements for clinical translation. In addition to this, the exorbitant costs of mRNA production imply that lower doses and less frequent dosing regimens are more likely to gain favourable reception. As such, dramatic advances are seen for mRNA formulations as vaccines, in protein replacement therapies, and gene editing.

LNP formulations containing mRNA are ideal vaccines. The development is conceptually straightforward and potentially very rapid. Preclinical evidence of using LNP-mRNA as vaccines against infectious diseases or cancer is extensive and several clinical trials have been initiated, including vaccines to combat the current COVID-19 pandemic. Since most vaccine applications rely on intramuscular or intradermal administration and the focus of this review is gene regulation in the liver, the reader is referred to several recent articles \[[@bb0965], [@bb0970], [@bb0975], [@bb0980], [@bb0985], [@bb0990], [@bb0995], [@bb1000]\]. However, several recent studies have used the "liver as a bioreactor" to produce relevant neutralizing antibodies.

Pardi *et al.* showed that intravenous delivery of LNP-mRNA encoding a broadly neutralizing antibody against HIV-1 resulted in sufficient expression to protect from HIV-1 challenge \[[@bb1005]\]. Similarly, another study showed that an LNP-mRNA system as prophylactic and therapeutic anti-rabies intervention protected mice from a Rabies virus challenge \[[@bb1010]\]. The prophylactic treatment involved a single dose 40 μg LNP-mRNA encoding an anti-rabies antibody intravenously administered one day prior to a 5-fold LD~50~ insult of Rabies virus (*i.m.*). The therapeutic intervention (at the same mRNA dose) was given 2 h post-Rabies virus challenge. In the same study, LNP-mRNA encoding a neutralizing antibody afforded complete protection to mice six hours following a botulinum neurotoxin challenge (4x LD~50~). Finally, this study also showed that LNP-mRNA encoding rituximab administered intravenously (at 10 or 50 μg mRNA) following a lethal challenge of Raji cells, resulted in either tumor growth deceleration or almost completely abolished tumor development.

LNP-based mRNA formulations have shown strong promise as therapeutics in disease states where genetic mutations result in a non-functional protein. Delivering exogenous (and functional) mRNA to generate a functional protein can alleviate stress from certain diseases. Initial studies that showed clear clinical utility are briefly highlighted here: Intravenous administration of LNP-mRNA encoding erythropoietin (EPO) resulted in increased EPO serum levels corresponding to increased reticulocyte, and elevated hematocrit in porcine and non-human primate (NHP) models \[[@bb1015]\]. Similarly, delivering mRNA encoding human clotting factor IX (FIX) to FIX-knockout mice displayed a reduction in hematocrit loss following injury, indicating FIX expression can rescue hemophilia B phenotypes \[[@bb1020]\].

Gene editing is the next major application of mRNA therapeutics. Various approaches have been explored including CRISPR/Cas9 and zinc-finger nucleases (ZFN). An initial gene editing demonstration used a combination of viral delivery (sgRNA and repair template) combined with LNP-mRNA encoding Cas9 to correct a mutation in the fumarylacetoacetate hydrolase gene \[[@bb1025]\]. The study showed approximately 6% of hepatocytes were edited and it is assumed that the limitation was the viral delivery. Comparatively, Finn *et al.* used LNP-mRNA formulations encoding for Cas9 protein, co-delivered with sgRNA targeting *ttr.* They showed sustained 12-month circulating TTR knockdown (97%) following a single administration of 3 mg/kg RNA body weight in a murine model with \~70% editing in the liver (\~70% liver cells are hepatocytes) \[[@bb1030]\]. Similarly, LNP-mediated delivery of mRNA encoding ZFN targeting *ttr* and *pcsk9* resulted in \> 90% knockout at mRNA doses 10-fold lower than reported previously \[[@bb0685]\]. In the same study, co-delivery of LNP-mRNA encoding ZFN targeting the albumin gene and a viral vector for templates of promotor-less human *IDS* or *FIX* resulted in integration of those templates at the albumin locus and generated therapeutically relevant levels of those proteins in murine models. In addition to continuous efforts in optimizing ionizable cationic lipids for enhanced genome editing in the liver, a recent study by Cheng *et al.* demonstrated that bioengineering LNP formulations with additional lipids, so-called selective organ targeting (SORT) molecules, can tune the LNP\'s efficiency and biodistribution. Adding 20 mol% of an ionizable cationic lipid such as DODAP significantly enhanced the genome editing in the liver, while addition of cationic or anionic SORT molecules enabled specific gene regulation in the lung or spleen \[[@bb1035],[@bb1040]\].

5. Clinical translation of lipid nanotechnology {#s0105}
===============================================

The rapid translation from lab bench to patients was primarily driven by a holistic design of LNP composition and processes to support scalability while maintaining potency. Onpattro® paved the way for the next generation of lipid-based therapeutics and its success in phase 2 trials spurred development of mRNA therapeutics. Gene therapies enabled by LNPs are under clinical development for a broad range of applications ([Table 4](#t0020){ref-type="table"} ) \[[@bb1055]\]. In this section we discuss the clinical data for Onpattro® and some mRNA therapeutics currently under development.Table 4Highlighted LNP-based nucleic acid therapeutics in the clinic. Drug products in clinical development or approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Company code names, generic (non-proprietary) names and company names for the products are given in brackets. Table adapted from Kulkarni *et al*. \[[@bb0090]\]Table 4ProductNucleic acid / transgeneIndicationAdministration routeClinical stageRef.**Gene silencing**Onpattro®, patisiran (Alnylam Pharmaceuticals)siRNA-TTRATTRv amyloidosisIntravenousApproved (2018)\[[@bb1115]\]ALN-VSP02 (Alnylam/Ascletis)siRNA-VSP/VEGF-ASolid tumors (liver involvement)IntravenousPhase I (completed)\
NCT01158079\
\[[@bb1120]\]ARB-001467 (Arbutus Biopharma)Three siRNAs against four HBV transcriptsHepatitis BIntravenousPhase 2 (completed)\
NCT02631096\[[@bb1125]\]TKM-080301, TKM-PLK1 (Arbutus Biopharma)siRNA-PLK1Solid tumors (NET, ACC)IntravenousPhase 1/2 (completed)\
NCT01262235\[[@bb1130]\]Atu027 (Silence Therapeutics)siRNA-PKN3 (+gemcitabine)Advanced / metastatic pancreatic cancerIntravenousPhase 1/2 (completed)\
NCT01808638\[[@bb1135]\]ND-L02-s0201, BMS-986263 (Nitto Denko Corporation / Bristol-Myers Squibb)siRNA-HSP47Idiopathic pulmonary fibrosisIntravenousPhase 2 (recruiting)\
NCT03538301\[[@bb1140]\]EPHARNA (M.D. Anderson Cancer Center)siRNA-EphA2Advanced or recurrent solid tumorsIntravenousPhase 1 (recruiting)\
NCT01591356\[[@bb1145]\]**Gene expression**Lipo-MERIT (Biontech RNA Pharmaceuticals)Four mRNAs encoding melanoma-associated antigensMelanomaIntravenousPhase 1 (recruiting)\
NCT02410733\
\[[@bb1150]\]IVAC_W\_bre1_uID and IVAC_M\_uID (Biontech RNA Pharmaceuticals)mRNAs encoding tumor-associated antigens and/or personalized neoantigensTriple negative breast cancerPhase 1 (recruiting)\
NCT02316457SGT-53 (SynerGene Therapeutics)pDNA encoding wild-type p53 (+nab-paclitaxel / gemcitabine)Metastatic pancreatic cancerIntravenousPhase 2 (recruiting)\
NCT02340117\
\[[@bb1155]\]MTL-CEBPA (Mina Alpha)saRNA-CEBPαAdvanced liver cancerIntravenousPhase 1 (recruiting)\
NCT02716012\[[@bb1160]\]**Gene editing**NTLA-2001 (Intellia Therapeutics / Regeneron)sgRNA-TTR\
mRNA-Cas9ATTRv amyloidosisIntravenousPhase 1\
planned\[[@bb1165]\]

The Onpattro® story, while heavily reviewed in literature, makes for a compelling case to support the development of other LNP nucleic acid formulations \[[@bb0165]\]. Initial efforts laid the foundations to support further clinical development, although it was clear that improved potency was required. DLinDMA-based LNP-siRNA against *ttr* (ALN-TTR01) was administered once to 24 healthy subjects at doses ranging from 0.01 to 1.0 mg siRNA per kg body weight, with another eight subjects receiving placebo \[[@bb1060],[@bb1065]\]. Over the period of 30 days, 38% serum TTR reduction was observed with persistent reduction for approximately one week. While the knockdown was arguably insufficient for therapeutic efficacy at the highest dose, the study validated the RNAi approach in humans. Subsequent clinical development used MC3-based LNP, named ALN-TTR02 or Onpattro® (patisiran). Another phase 1 study included 13 healthy subjects receiving Onpattro®, four subjects receiving placebo, and another six receiving a control siRNA \[[@bb1070]\]. The Onpattro® doses ranged from 0.01 to 0.5 mg/kg siRNA and TTR serum levels were measured over 70 days. At siRNA doses of 0.3 mg/kg, rapid and robust *ttr* knockdown was observed; this was sustained over two weeks for a period of 21 days following administration. At these doses and with promising results, further development was warranted.

In a subsequent phase 2 study, the dosing regimen for Onpattro® was established \[[@bb0430]\]. ATTRv patients received two Onpattro® infusions at doses 0.01-0.3 mg/kg every four weeks or 0.3 mg/kg every three weeks. The Q3W dosing regimen resulted in a mean 85% knockdown after the second dose. Only few mild-to-moderate infusion-related reactions were observed and one patient reported three serious adverse events. The similarity to preclinical data is quite astonishing; in NHP studies, increasing dosing frequency to Q3W (from Q4W) resulted in 96% maximal knockdown, and \~85% mean knockdown following the initial dose \[[@bb0960]\].

In the phase 3 APOLLO study, 148 patients received Onpattro® at a dose of 0.3 mg/kg once every three weeks, with 77 patients receiving placebo \[[@bb0160]\]. The primary endpoint was the modified neuropathy impairment score + 7 (mNIS + 7), which is used to measure the level polyneuropathy in ATTRv patients. The test uses highly standardized, quantitative methods to measure muscle weakness, muscle stretch reflexes, sensory loss, and autonomic impairment with higher scores corresponding to disease worsening \[[@bb1075]\]. Over a period of 18 months, ATTRv patients on placebo showed a linear increase in their mNIS+7 from 0 to 28.0. Onpattro®, with an mNIS+7 of -6.0, is the only ATTRv treatment that has been able to halt and even reverse disease progression in patients \[[@bb0160]\]. In addition to this, Onpattro® also met all secondary endpoints. This led to EMA and FDA approval in August 2018 \[[@bb0165]\].

With LNP technology validated as a safe approach for gene modulation in the liver, a wide range of applications have emerged. A substantial effort is focusing on vaccine applications without necessarily transfecting the liver. However, the potential for treating liver diseases is also clear. Translate Bio was developing a formulation for treating OTC deficiency, however disappointing preclinical toxicology data resulted in the termination of the program \[[@bb1080]\]. Moving forward, they chose to focus on developing their cystic fibrosis mRNA therapeutic. Moderna Therapeutics is advancing an LNP candidate formulation for treating methylmalonic acidemia \[[@bb1085]\]. The focus of this review is on the hepatic applications of LNP formulations, and indications for extrahepatic targets have been summarized elsewhere \[[@bb1090]\]. Highlighted LNP-based nucleic acid therapeutics in the clinic are summarized in [Table 4](#t0020){ref-type="table"}.

5.1. Overcoming the barriers to successful clinical translation {#s0110}
---------------------------------------------------------------

Therapeutic development, and gene therapy in particular, requires concerted efforts from formulation developers, process developers, and clinical sponsors to allow for successful clinical translation. Specifically, the therapeutic has to be safe and effective, be producible at a large scale, and meet all regulatory requirements for the corresponding drug class. Onpattro® has shown that this is possible for systemic nucleic acid therapeutics, as it overcame barriers that typically halt the clinical translation of such nanocarrier-based therapeutics.

Intravenous administration of nanoparticulate formulations can potentially result in infusion-related reactions such as hypersensitivity manifesting as mild flu-like symptoms, or more severe cardiac anaphylaxis \[[@bb1095]\]. Both complement activation as well as complement-independent phagocytosis are involved in such reactions. The reader is referred to excellent articles on complement activation-related pseudoallergy (CARPA) and complement independent pseudoallergy (CIPA) \[[@bb1095],[@bb1100]\]. Several physiochemical properties such as lamellarity, surface charge, and cholesterol content may influence hypersensitivity reactions \[[@bb1105]\]. Infusion-related reactions can be managed by pre-dosing patients with a combination of anti-histamines (H1/H2 blockers), corticosteroid immunosuppressants (*e.g.*, dexamethasone), and oral acetaminophen in addition to reducing the rate of infusion \[[@bb1110]\]. Onpattro®'s phase 3 trial suggested that the most frequent reactions included flushing, backpain, abdominal pain, and nausea described as mild-to-moderate. The severity and frequency of these reactions decreased with repeated administration and exposure of Onpattro®. It should be noted that ASOs and GalNAc-siRNA conjugates do not require pre-medication and can be administered subcutaneously (by healthcare professionals), but the doses required to achieve equivalent gene silencing are a few orders of magnitude higher than required for LNPs and can only be limited to gene silencing applications \[[@bb0960]\].

Another substantial barrier to clinical translation is producing formulations at commercial scales. As described previously, LNP manufacturing methods rely on rapid-mixing technologies and therefore, the type and capabilities of the mixer become very important. For example, a production of 10 mL LNP-siRNA at a flow rate of 20 mL/min requires a mixing time of 30 seconds \[[@bb0785]\]. However, production of 1 L of material with the same mixer requires 50 minutes of mixing time. With an inherently unstable LNP suspension and in 25% (v/v) ethanol, this time could result in substantial changes in LNP properties negating the value of rapid-mixing technologies (homogeneity). High-throughput mixers (\> 1 L/min) are required to mitigate such effects. In addition to this, the in-process volumes generated by rapid-mixing are much larger than by extrusion and can be limiting to manufacturing scales. Typical processes use low concentrations of material (0.2 mg/mL siRNA after mixing), and therefore the intermediate volumes are substantial. For example, 1 g siRNA (only 100 vials of Onpattro®) would generate 5 L of material post-mixing and would include a post-mixing dilution step to stabilize the intermediate material. This could result in up to 15-20 L of intermediate material depending on the required dilution (composition-dependent). For larger batches, even the ethanol amount handled at a facility can become limiting. Following this, the next processing steps introduce shear as buffer exchange is not done by dialysis, but rather by tangential flow filtration. Given the inherent instability of these formulations, particle size increases are observed during this step. These processes use terminal, redundant sterile filtration rather than complete aseptic processing. The impact that buffer exchange has on particle size also affects the ability to sterile filter the formulation and the yield of material. Robust process design is critical for successful and timely clinical translation of such formulations.

6. Future perspectives {#s0115}
======================

Developing LNP delivery technology has enabled the clinical translation and approval of the first siRNA drug for inhibiting pathogenic protein production in hepatocytes \[[@bb0160],[@bb0165]\]. Importantly, Onpattro® provides a valuable treatment for ATTRv amyloidosis patients, whose options were previously limited to TTR stabilizers or a liver transplant \[[@bb0170]\]. At the same time, LNP-siRNA development has yielded fundamental insights into optimally designing formulations for hepatocyte gene silencing, (large scale) production methods, *in vivo* behaviour, immunostimulatory effects, and cost-effectiveness. As these criteria and parameters are now firmly established, it is anticipated that other hepatocyte-targeted LNP-siRNA treatments will be developed, such as to knockdown proprotein convertase subtilisin/kexin type 9 for hypercholesteremia treatment \[[@bb1170]\].

While these advances in LNP development are ground-breaking, other liver-targeted nucleic acid therapeutics, such as ASOs \[[@bb0015]\] and GalNAc-siRNA conjugates \[[@bb0020]\], are also gaining momentum. For example, the ASO Tegsedi® (inotersen) was recently approved for the same indication as Onpattro® \[[@bb1175]\]. With both Onpattro® and Tegsedi® set at the same list price (\$450,000 per year), it remains to be seen which treatment will prove to be most beneficial and cost-effective. Tegsedi's® major advantage is its subcutaneous administration (versus Onpattro's® intravenous infusion), although this advantage could be outweighed by its less favorable toxicity profile; patients require monitoring of platelet count, renal and hepatic impairment. Subcutaneous administration (and a less complex production process) is also the main advantage of GalNAc-siRNA conjugates although currently approved conjugates have to be administered by healthcare professionals. Most recently, the GalNAc-siRNA conjugate Givlaari™ (givosiran, \$575,000 per year) was approved for treating acute hepatic porphyria \[[@bb1180],[@bb1185]\], while New Drug Applications were filed for lumasiran for treating primary hyperoxaluria type 1, \[[@bb1190],[@bb1195]\] and inclisiran for treating hypercholesteremia \[[@bb1200], [@bb1205], [@bb1210]\]. Vutrisiran, a GalNAc-siRNA conjugate for treating ATTRv amyloidosis, is currently undergoing phase 3 trials and has been granted Orphan Drug designation in the U.S. and the European Union \[[@bb1215]\]. Although there is preclinical evidence that LNP-siRNA can induce hepatic gene silencing following subcutaneous administration, the dose needed for effective gene silencing is considerably higher than for intravenously administered formulations \[[@bb0735]\]. Of note, while LNP-siRNA systems have been optimized for hepatic gene silencing, preclinical studies have also demonstrated their ability to induce effective gene silencing in extrahepatic target sites including the bone \[[@bb1220]\] and tumors \[[@bb1225],[@bb1230]\]. A major area of interest is applying LNP-siRNA for immunotherapy, by silencing target genes in lymphocytes following intravenous administration for immunotherapy \[[@bb1235], [@bb1240], [@bb1245], [@bb1250], [@bb1255]\] (covered by Peer *et al.* in this issue \[[@bb1260]\]).

As mentioned before, LNP technology's true benefits are currently proving to be of significant value for gene regulation approaches using large nucleic acid-based therapeutics, such as mRNA and gene editing complexes, which cannot be accomplished by nucleic acid modification or GalNAc conjugation. Intravenously administered LNP-mRNA effectively transfect hepatocytes and induce protein expression in the liver, providing opportunities for protein replacement therapy without affecting the genome. For example, An *et al.* demonstrated that treatment with LNP containing mRNA encoding human methylmalonyl-CoA mutase (hMUT) had sustained functional benefits in mouse models of methylmalonic acidemia, a rare, inherited, pediatric metabolic disorder \[[@bb1085]\]. Other examples include using the liver to produce coagulation factors \[[@bb1265]\], or therapeutic antibodies against HIV \[[@bb1005]\] and chikungunya virus \[[@bb1270]\]. Although this review focuses on gene therapy for diseases originating in the liver, it is worth mentioning that as with LNP-siRNA, intravenously injecting LNP-mRNA to induce protein expression in immune cells is gaining considerable traction \[[@bb1275],[@bb1280]\], especially for developing (personalized) cancer immunotherapies \[[@bb1285],[@bb1290]\]. In addition, LNP-mRNA systems have revealed their potential for *ex vivo* CAR T cell engineering \[[@bb1295]\].

Moreover, LNP-mRNA-based vaccinations following subcutaneous, intradermal, or intramuscular administration have demonstrated to effectively protect from viral challenge \[[@bb1300], [@bb1305], [@bb1310], [@bb1315], [@bb1320], [@bb1325]\]. Given mRNA's relatively short optimization time from target identification to therapeutic, several companies including Moderna, BioNTech, and CureVac as well as universities around the globe have initiated LNP-mRNA vaccine programs to combat the recent SARS-CoV-2 pandemic \[[@bb1330], [@bb1335], [@bb1340], [@bb1345]\]. Typical vaccine production relies on isolation and large-scale virus propagation with subsequent processing to purify material (*e.g.* inactive virus or specific surface protein) that raises a response against a specific viral antigen. With mRNA delivery, these timelines can be dramatically reduced, and the breadth of immune coverage expanded. Additionally, mRNA vaccines leverage several aspects of LNP technology: (1) LNP systems are not completely immune-silent and can act as adjuvants \[[@bb1350],[@bb1355]\], (2) few doses are required (*i.e.* prime and booster), and (3) the mRNA dosage is relatively low (compared to protein replacement therapies).

LNP technology, and ionizable cationic lipid development in particular, have been instrumental for translating therapeutic gene regulation in hepatocytes from bench to bedside. As LNPs are a multicomponent and modular platform, they represent a versatile toolbox with many opportunities to develop future gene therapies with more potent therapeutic effects and improved toxicity profiles. For example, incorporating lipophilic prodrugs in LNP systems has shown to be an attractive approach for reducing nucleic acid therapeutics' immunostimulatory effects \[[@bb1360]\] or for designing combination therapies with additive therapeutic effects \[[@bb1365]\]. Generating more potent (ionizable cationic) lipids and improved understanding of nano-bio interactions *in vivo* are continuously fueling the optimization of LNP systems for delivering nucleic acid therapeutics. Deciphering intracellular trafficking pathways and mechanism(s) of endosomal escape will facilitate efforts to boost LNP potency \[[@bb1370], [@bb1375], [@bb1380], [@bb1385]\]. Elucidating the nature and dynamic of the biomolecular corona formed on LNPs (following intravenous injection) and understanding its implications for biodistribution will be crucial to develop gene therapies beyond the liver \[[@bb0810], [@bb0815], [@bb0820],[@bb1390],[@bb1395]\]. Therefore, we expect that LNP-based gene therapies will be developed for indications beyond (ultra) rare diseases in the near future and increasingly become integrated in mainstream medicine.

Acknowledgements {#s0120}
================

PRC acknowledges support from the Canadian Institutes for Health Research (FDN 148469) and the NanoMedicines Innovation Network (NMIN), a Canadian Networks of Centres of Excellence (NCE) in nanomedicine. DW is supported by the 10.13039/501100001711Swiss National Science Foundation (\#183923). JAK is supported by the NMIN Postdoctoral Fellowship Award in Gene Therapy. JL is supported by a Frederick Banting and Charles Best Canada Graduate Scholarship -- Masters (6556). The work of RvdM is supported by the Netherlands Organization for Scientific Research (NWO, ZonMW Vici grant no. 016.176.622).

Declaration of Competing Interest {#s0125}
=================================

PRC is a co-founder of Acuitas Therapeutics and Precision Nanosystems; and Scientific Director and CEO of the NMIN.

Contributions {#s0130}
=============

DW, JAK, JL, SC, PRC and RvdM conceived and co-wrote the manuscript. The final manuscript was approved by all authors.

[^1]: Equal contribution.
